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–15.5 to 3.7, p = 0.214) and QT dispersion (median –3.0 ms, 
95% CI –13.0 to 7.0, p = 0.536) compared to the control 
group. No significant association between change in QTc 
and change in QT dispersion, respectively, and change in 
possible confounders was found.  Conclusion: LVRS seems to 
have no effect on cardiac repolarization in patients with 
COPD. Thus, lung hyperinflation seems not to be a causal 
mechanism for altered cardiac repolarization in COPD pa-
tients.  © 2016 S. Karger AG, Basel 
 Introduction 
 Cardiovascular disease plays an important role regard-
ing the morbidity and mortality in patients with chronic 
obstructive pulmonary disease (COPD)  [1–3] . It has been 
suggested that the rate of sudden cardiac death (SCD) is 
two- to threefold increased in patients with COPD  [4] . A 
recently published cross-sectional study by our group 
found that a high prevalence of COPD patients showed 
altered cardiac repolarization and increased dispersion of 
repolarization, potentially exposing these patients to an 
increased risk of malignant ventricular arrhythmias and 
SCD  [5] .
 Key Words 
 Airflow limitation · Cardiac repolarization · Chronic 
obstructive pulmonary disease · Sudden cardiac death · 
Surgery for emphysema 
 Abstract 
 Background: Altered cardiac repolarization is a risk factor for 
sudden cardiac death and seems to be increased in chronic 
obstructive pulmonary disease (COPD) patients.  Objective: 
Lung volume reduction surgery (LVRS) has been shown to 
improve breathing mechanics and lung function in patients 
with severe COPD and emphysema and possibly also im-
prove altered cardiac repolarization.  Methods: Thirty pa-
tients scheduled for LVRS were randomized to LVRS or to the 
control group. We investigated the treatment effect 3 
months after LVRS on measures of cardiac repolarization and 
dispersion of repolarization (QTc interval, QT dispersion) de-
rived from electrocardiography. Univariable and multivari-
able analyses were used to identify possible confounders in-
fluencing the treatment effect.  Results: LVRS  was associated 
with an improvement in lung function (mean ± SD residual 
volume/total lung capacity of –9 ± 11% and forced expira-
tory volume in 1 s of +30 ± 29%). LVRS did not significantly 
reduce QTc (median –5.3 ms, 95% confidence interval, CI 
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 Prolonged cardiac repolarization is associated with the 
development of fatal arrhythmias and the occurrence of 
SCD  [6–8] . Different measures derived from electrocar-
diography (ECG) represent repolarization inhomogene-
ities of the myocardium such as QT interval and QT dis-
persion  [8, 9] . In diverse patient populations, an associa-
tion between altered cardiac repolarization and the 
development of malignant arrhythmia and SCD, respec-
tively, has been documented  [10–12] .
 The degree of airflow limitation measured by forced 
expiratory volume in 1 s (FEV 1 ) is associated with a high-
er risk of ischemic heart disease and SCD, even after ad-
justing for the cardiovascular risk profile  [13, 14] . Fur-
ther, COPD patients seem to have a higher frequency of 
arrhythmias, and the severity of airflow obstruction seems 
to be associated with the occurrence of arrhythmia in 
COPD patients  [15, 16] .
 A small case-control study with 30 COPD patients and 
31 age- and sex-matched control subjects showed an as-
sociation between increased maximal QT interval and the 
development of ventricular arrhythmia  [17] . However, 
the mechanisms contributing to altered cardiac repolar-
ization in patients with COPD are still a matter of debate.
 Apart from lung transplantation, lung volume reduc-
tion surgery (LVRS) is currently the only treatment that 
significantly improves airflow obstruction, but this ther-
apy is reserved for a highly selected group of patients with 
end-stage COPD. The aim of this study was to evaluate 
the treatment effect of LVRS on cardiac repolarization 
and to investigate possible influencing factors in a group 
of severe COPD patients.
 Methods 
 Study Design and Subjects 
 The current analysis was a sub-study of a randomized con-
trolled trial (RCT) evaluating the effect of LVRS on endothelial 
function in patients with severe COPD  [18] . Randomization was 
performed 1: 1 to intervention or control group. Patients with 
COPD (GOLD stages 3–4) planned for LVRS were randomized to 
one of two groups: group 1 receiving immediate LVRS (surgical 
approach described in the online suppl. material; for all online 
 suppl. material, see www.karger.com/doi/10.1159/000445030) 
and group 2 receiving LVRS after a delay of 3 months. The same 
outcomes were measured at baseline and 3 months after LVRS and 
no therapy (control group), respectively ( fig. 1 ). Sealed envelopes 
were used for the allocation procedure by M.K. No minimization 
was performed.
 Patients between 40 and 75 years referred for evaluation of 
LVRS were included in the study at the University Hospital of Zu-
rich, Switzerland, between November 2009 and April 2014. Elec-
tion for LVRS was based on previously published criteria from the 
National Emphysema Treatment Trial  [19] and interdisciplinary 
discussion with the department of thoracic surgery. Homogeneous 
Identification of
LVRS candidates
40 assessed for
eligibility
30 randomized for
baseline evaluation
1 withdrew participation
1 no ECG at follow-up
15 immediate LVRS
3 no ECG at follow-up 3 months
Excluded
9 declined participation
1 language difficulties
15 usual care
12 follow-up 13 follow-up
 Fig. 1. Study flowchart. 
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emphysema types were not generally excluded. Patients with an 
exacerbation within the last 6 weeks and mentally or physically 
disabled persons precluding informed consent or compliance with 
the protocol were also excluded.
 The study was conducted in accordance with the declaration of 
Helsinki of the World Medical Association. The Ethics Committee 
of the Canton of Zurich approved the study (EK-ZH-NR: 1734) 
and all subjects gave written informed consent to participate. The 
study was registered at clinicaltrials.gov (NCT01020344).
 Measurements 
 Cardiovascular Risk and Medication 
 The cardiovascular risk profile was assessed by the Pocock risk 
score, which predicts the individuals’ 5-year risk of death due to a 
cardiovascular cause  [20] . This score includes 11 cardiovascular 
risk factors, including sex, age, smoking status, systolic blood pres-
sure, cholesterol, creatinine, height, diabetes, previous myocardial 
infarction, stroke and left ventricular hypertrophy. Brain natri-
uretic peptide (BNP) was measured from fresh plasma samples. 
Patients were asked if they used QT interval affecting medications 
according to the International Registry of Drug-Induced Arrhyth-
mias maintained by the Georgetown University  [21] .
 Blood Pressure and Heart Rate 
 Blood pressure and heart rate were measured after resting in 
supine position for 5 min with a validated blood pressure monitor 
(Omron Healthcare, Kyoto, Japan) in a quiet room. The average of 
three readings separated by 1-min intervals was used for analysis.
 Respiratory Variables 
 Standard pulmonary functional testing was performed accord-
ing to American Thoracic Society guidelines  [22] to measure FEV 1 , 
forced vital capacity (FVC), total lung capacity (TLC), residual vol-
ume (RV) and diffusing capacity of the lung for carbon monoxide 
(DLCO). Daytime arterial oxygen saturation (SaO 2 ) was measured 
by arterial blood gas analysis (ABL 700 series, Radiometer Copen-
hagen) after 5 min of rest.
 Electrocardiography 
 Patients were asked to abstain from alcohol, tobacco or caffeine 
on the day the measurements were taken. All participants had to 
rest in supine position for at least 5 min before measurements were 
started. ECG was recorded with a 12-lead ECG (AT 104 PC, Schil-
ler-Reomed AG, Switzerland) set at 25-mm/s paper speed and 10-
mm/mV amplitude. Measurements of the ECG intervals were per-
formed twice with dedicated ECG analysis software (DatInf ® Mea-
sure 2.1d, DatInf GmbH, Tübingen, Germany) by two investigators 
who were blinded to the patient’s data as previously described  [23] . 
The mean of the ECG interval measurements by the two investiga-
tors was calculated and used for statistical analysis. Four consecu-
tive heart cycles were evaluated for each lead. The mean value for 
each lead of the twelve leads was calculated.  Figure 2 illustrates the 
calculation of repolarization measures. The QT interval was de-
fined as the time from the earliest onset of the QRS complex to the 
end of the T wave  [24] . The end of the T wave was defined as the 
cutting point of the tangent to the downward slope of the T wave 
and the isoelectric line  [25] . As a measurement of dispersion of 
repolarization, QT dispersion was defined as the difference be-
tween the lead with the maximal and the lead with the minimal QT 
interval duration  [26] . QT interval corrected for heart rate (QTc) 
was corrected for heart rate by using the Bazett formula  [27] .
 Data Analysis and Statistics 
 Data analysis was performed on a per-protocol basis. All results 
are shown as mean values ± standard deviation (SD) or median 
(quartiles) unless otherwise stated. Statistical analysis was per-
formed with STATA 14 (StataCorp, College Station, Tex., USA). 
The treatment effect on cardiac repolarization was analyzed using 
multivariable regression models adjusting for treatment group and 
the corresponding baseline value. Further, univariable regression 
models were used to analyze the influence of treatment effect in 
possible confounders on cardiac repolarization. A post hoc analy-
sis was performed to adjust change in cardiac repolarization for 
possible imbalances in baseline characteristics. A two-sided p val-
ue of <0.05 was considered to be statistically significant.
 Results 
 Study Participants 
 Of the 40 patients screened for eligibility, 30 were in-
cluded for baseline examination ( fig.  1 ). Five patients 
were lost to follow-up. Of these, 1 patient withdrew par-
ticipation and 4 patients (1 in the control group and 3 in 
the intervention group) had no ECG at follow-up. The 
baseline patient characteristics are shown in  table  1 . 
R
P
T
Q
S
QT interval
 Fig. 2. The length of the QT interval was obtained by identifying 
the QRS onset and the point at which the downward slope of the 
T wave returns to baseline. 
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There were no changes in relevant medications poten-
tially influencing cardiac repolarization during the study 
period.
 Surgical Approach, Complications and 
Hospitalization Time 
 Of the 12 patients in the intervention group included 
in the per-protocol analysis, 5 patients received bilateral 
LVRS of the upper lobes, 2 patients received unilateral 
LVRS of the right upper lobe and 4 patients received 
LVRS of right lower lobe (2 of them received additional 
resection of one segment of the middle lobe). LVRS on 
the left lower lobe was performed in 1 subject.
 In 2 patients, a pneumothorax occurred after removal 
of thoracic drainage and resolved without further compli-
cations after drainage, and in 2 cases, a persistent fistula 
had to be oversealed 14 days after LVRS. One of the pa-
tients with a persistent fistula had the longest hospitaliza-
tion time (28 days), while the mean hospitalization time 
after surgery was 14 days (range 7–28).
Control group
(n = 13)
Intervention group
(n = 12)
Demographics and cardiovascular risk
Age, years 65 ± 6.1 64 ± 8.8
Male 9 (69) 7 (58)
Body mass index 23.9 ± 2.8 23.3 ± 5.2
Pack-years of smoking 53 ± 12.7 38 ± 7.8
Systolic blood pressure, mm Hg 130 ± 11.9 130 ± 9.3
Diastolic blood pressure, mm Hg 79 ± 10.2 86 ± 9.7
Heart rate, bpm 90.4 ± 15.0 78.1 ± 14.8
Arterial hypertension 16 (64) 9 (36)
Arrhythmia 2 (15) 1 (8)
Diabetes 3 (23) 3 (25)
Coronary artery disease 5 (38) 2 (17)
Pocock risk score, % 2.4 ± 1.4 2.1 ± 1.6
Respiratory variables
FEV1, % pred. 26 ± 5.9 27 ± 5.2
FVC, % pred. 68 ± 15.7 68 ± 10.8
TLC, % pred. 129 (119.0 – 130.0) 126 (118.5 – 150.5)
RV/TLC, % 67 ± 5.6 68 ± 4.6
DLCO, % pred. 35 ± 5.1 34 ± 8.3
SaO2, % 94 (91.6 – 95.9) 95 (94.1 – 95.5)
Medication
QT-affecting drug 3 (23) 3 (27)
Antihypertensive drug 9 (69) 5 (42)
Beta-blocker 2 (15) 0 (0)
Cholesterol-lowering drug 4 (31) 3 (25)
LAMA only 0 (0) 0 (0)
LAMA + GC 0 (0) 1 (8)
LABA only 1 (8) 0 (0)
LABA + GC 0 (0) 0 (0)
LAMA + LABA 0 (0) 1 (8)
LAMA + LABA + GC 12 (92) 10 (83)
Laboratory parameters
BNP, mg/l 93 (73.0 – 185.0) 110 (48.5 – 152.0)
ECG parameters
QTc, ms 436.4 ± 19.5 433.2 ± 13.4
QT dispersion, ms 34.9 ± 9.0 37.9 ± 12.1
 Values are expressed as mean ± SD, n (%) or median (95% CI). LAMA = Long-acting 
muscarinic antagonist; LABA = long-acting beta-agonist; GC = glucocorticoids.
 Table 1.  Baseline characteristics
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 Treatment Effect on Cardiac Repolarization Measures 
 LVRS led to no significant reduction in median QTc 
of –5.3 ms (95% confidence interval, CI –15.5 to 3.7, p = 
0.214) and QT dispersion of –3.0 ms (95% CI –13.0 to 7.0, 
p = 0.536), respectively, compared to the control group 
( table 2 ). The individual results on QTc duration and QT 
dispersion according to randomization are illustrated in 
 figure 3 a and b, respectively. A post hoc analysis showed 
no significant interaction between the treatment effect on 
QTc and QT dispersion, respectively, and age, gender, 
heart rate, arterial hypertension, arrhythmia, FEV 1 % 
pred., SaO 2 , the use of antihypertensive medication, the 
use of beta-blockers and the use of medications affecting 
the QT interval, respectively.
 Only 1 patient in the intervention group and 3 patients 
in the control group showed a prolonged QTc (>450 ms) 
at baseline. After LVRS, QTc was normalized in the pa-
tient with previously prolonged QTc, whereas in the con-
trol group, no relevant changes were observed. No patient 
showed a prolonged QT dispersion >60 ms at baseline or 
at follow-up.
475
450
425
400
375
0
Baseline
p = 0.214
Control groupa
Q
Tc
 d
ur
at
io
n 
(m
s)
After 3 months Baseline
Intervention group
After 3 months
70
50
60
20
10
30
40
0
Baseline
p = 0.536
Control groupb
Q
T 
di
sp
er
si
on
 (m
s)
After 3 months Baseline
Intervention group
After 3 months
 Table 2. Primary outcomes
Control group (n = 13)  Intervention group (n = 12) Treatment 
effect 
(95% CI)
Adjusted 
treatment 
effecta 
(95% CI)
p value 
for adjusted 
treatment 
effect
baseline follow-up change ba seline follow-up change
QTc, ms 436.4 ± 19.5 436.4 ± 20.9 –0.0 ± 13.0 433.2 ± 13.4 427.9 ± 13.3 –5.3 ± 10.1 –5.3 
(–15.0 to 4.4)
–5.9 
(–15.5 to 3.7)
0.214
QT dispersion, ms 34.9 ± 9.0 36.3 ± 11.8 +1.4 ± 13.2 37.9 ± 12.1 33.1 ± 11.5 –4.8 ± 18.9 –6.2 
(–19.6 to 7.3)
–3.0 
(–13.0 to 7.0)
0.536
a Adjusted for baseline QTc and QT dispersion, respectively.
 Fig. 3. QTc ( a ) and QT dispersion ( b ) values of individual patients are presented for the control group and the 
intervention group. The solid bars represent the mean QTc and QT dispersion, respectively, at baseline and after 
3 months (control group) and at baseline and after LVRS (intervention group). 
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 Treatment Effect on Possible Confounders 
 Table  3 shows the treatment effect on possible con-
founders. Systolic blood pressure showed a decrease of 
–9.0 mm Hg (95% CI –23.0 to +5.0, p = 0.198) in the in-
tervention group compared to the control group. LVRS 
led to a relative reduction in mean RV/TLC of –9 ± 11% 
and a relative increase in FEV 1 of 30 ± 29%. No significant 
differences in the change of SaO 2 were observed.
 Association between Treatment Effect on Cardiac 
Repolarization and Possible Confounders 
 No significant association between change in QTc and 
change in possible confounders such as blood pressure, 
heart rate, Framingham risk score, lung function vari-
ables, SaO 2 and BNP was found (online suppl. table S1). 
The change in QT dispersion was not significantly asso-
ciated with the change in possible confounders (online 
suppl. table S2).
 Discussion 
 This is the first RCT evaluating cardiac repolariza-
tion in COPD patients. LVRS has been shown to im-
prove breathing mechanics and lung function in pa-
tients with severe COPD and emphysema. The findings 
suggest that LVRS does not influence cardiac repolar-
ization in patients with COPD, and therefore, lung 
function impairment seems not to be a mechanism for 
altered cardiac repolarization in COPD patients. How-
ever, it still remains unclear if hypoxia may be a mecha-
nism leading to altered cardiac repolarization in pa-
tients with COPD.
 SCD is a major cause of cardiovascular mortality. Cor-
onary artery disease, cardiomyopathies, congenital heart 
disease and alteration of cardiac repolarization including 
the long QT syndrome are established risk factors for 
SCD  [28] .
 Table 3. Possible confounders for treatment effect
Control group (n = 13) Intervention group (n = 12) Adjusted 
treatment 
effecta 
(95% CI)
p 
value
baseline follow-up change ± SD baseline follow-up change ± SD
Clinical characteristics and cardiovascular risk
Systolic blood pressure, 
mm Hg
130.2 ± 11.9 134.2 ± 18.3 +4.0 ± 17.1 129.7 ± 9.3 124.8 ± 19.6 –4.9 ± 16.0 –9.0 
(–23.0 to 5.0)
0.198
Diastolic blood pressure, 
mm Hg
78.7 ± 10.2 81.2 ± 12.3 +2.5 ± 7.3 85.6 ± 9.7 79.9 ± 12.6 –5.7 ± 11.7 –6.9 
(–15.4 to 1.6)
0.108
Heart rate, bpm 90.4 ± 15.0 94.1 ± 12.3 +3.6 ± 15.3 78.1 ± 14.8 82.3 ± 12.6 +4.1 ± 13.3 –7.1
(–17.3 to 3.1)
0.164
Pocock risk score, % 2.4 ± 1.4 2.5 ± 1.8 +0.2 ± 0.8 2.1 ± 1.6 2.1 ± 1.5 –0.0 ± 0.6 –0.2 
(–0.8 to 0.5)
0.601
Lung function
FEV1, % pred. 26.2 ± 5.9 24.6 ± 6.5 –1.6 ± 3.9 27.4 ± 5.2 35.7 ± 9.1 +8.3 ± 7.9 +10.0 
(4.7 to 15.2)
0.001
FVC, % pred. 68.2 ± 15.7 69.0 ± 16.3 +0.8 ± 11.0 68.1 ± 10.7 84.3 ± 14.8 +16.3 ± 19.1 +15.4 
(3.6 to 27.2)
0.013
TLC, % pred. 129.0 
(119.0 to 130.0)
121.0 
(117.0 to 126.0)
+0.0 
(–5.0 to 3.0)
126.0 
(118.5 to 150.5)
124.0 
(117.0 to 142.5)
–4.0 
(–11.0 to 0.5)
+2.8 
(–9.3 to 15.0)
0.635
RV/TLC ratio 66.8 ± 5.6 66.6 ± 7.8 –0.2 ± 6.5 68.1 ± 4.6 61.8 ± 5.2 –6.3 ± 7.5 –5.3 
(–10.8 to 0.1)
0.053
DLCO, % pred. 34.6 ± 5.1 33.1 ± 5.2 –1.5 ± 4.6 34.0 ± 8.3 37.7 ± 10.3 3.7 ± 8.1 +5.0 
(–0.3 to 10.4)
0.064
Blood gas analysis
SaO2, % 93.7 
(91.6 to 95.9)
94.5 
(92.2 to 96.0)
+0.1 
(–0.5 to 1.4)
94.7 
(94.1 to 95.5)
94.8 
(92.5 to 96.5)
+0.4 
(–0.6 to 2.1)
+0.9 
(–0.9 to 2.8)
0.292
Laboratory parameters
BNP, mg/l 93.0 
(73.0 to 185.0)
108.0 
(61.0 to 181.0)
+0.0
(–51.0 to 18.0)
109.5 
(48.5 to 152.0)
89.5 
(59.0 to 131.5)
+5.5
(–32.5 to 47.5)
+31.6 
(–46.6 to 109.7)
0.410
a Adjusted for corresponding baseline value.
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 Both, altered QT interval and increased QT dispersion 
represent predictors of an elevated risk for malignant car-
diac arrhythmia and SCD  [11, 29] . The QT interval rep-
resents the time from onset of ventricular depolarization 
to completion of repolarization including the vulnerable 
period for reentry tachycardia. In practice, a QTc prolon-
gation to >450 ms has been identified as a risk factor for 
fatal ventricular arrhythmias and SCD  [29, 30] . QT dis-
persion is an index of the spatial differences in myocar-
dial recovery times. QT dispersion >60 ms promotes the 
development of malignant ventricular arrhythmias  [17] 
and SCD  [11] .
 To date, there are no other RCTs investigating possible 
determinants of altered cardiac repolarization and in-
creased cardiac repolarization dispersion in COPD pa-
tients. There are previous cross-sectional studies inves-
tigating potential predictors of increased cardiac repo-
larization dispersion in COPD patients  [17, 31–33] . 
However, the included patients were mostly free from co-
morbidities. A significant univariate association between 
QT dispersion and FEV 1 % pred. and FVC % pred., re-
spectively, has been documented in 246 patients with 
mild-to-moderate COPD  [31] . After correcting for co-
variates, this association did not remain statistically sig-
nificant. A previous study compared 30 COPD patients 
with and without increased QT dispersion regarding pos-
sible factors influencing QT dispersion and found no fac-
tors independently influencing QT dispersion  [17] . Con-
sistent with these findings, the previous cross-sectional 
study by our group showed no significant independent 
association between QT dispersion and possible influenc-
ing factors  [5] . Further, in the current study, there was no 
significant change in QT dispersion after LVRS com-
pared to the control group, and no significant association 
between QT dispersion and possible determinants 
changed by LVRS such as lung function and blood pres-
sure was found. Additionally, the current study does not 
show a significant difference in the change in QTc dura-
tion between the intervention and the control group, and 
no association between possible determinants and QTc 
duration was found.
 The findings of our previous study showed a signifi-
cant independent association between hypoxia and QTc 
duration indicating a possible mechanism of altered car-
diac repolarization duration in COPD patients  [5] . It has 
been assumed that hypoxia may prolong cardiac repolar-
ization duration. In a study with healthy volunteers by 
Roche et al.  [34] exposing them to normobaric hypoxic 
conditions, a significantly prolonged QTc interval due to 
hypoxia was found. Further, prolonged QTc interval was 
found in 12 COPD patients with low mean basal SaO 2 
(<80%)  [35] . In contrast, Sarubbi et al.  [33] measured 
QTc in 15 hypoxemic/hypercapnic COPD patients before 
and after oxygen therapy and showed no significant re-
duction of QTc duration after 1 day of oxygen supple-
mentation. Although the results of this RCT cannot con-
firm hypoxia as a mechanism for altered cardiac repolar-
ization in COPD patients, this might be because there was 
no significant change in oxygen saturation after LVRS in 
the current trial. Thus, it is still a matter of debate wheth-
er hypoxia affects cardiac repolarization, and the under-
lying mechanism through which hypoxia may possibly 
influence cardiac repolarization remains currently un-
known.
 As a limitation of this study, no continuous 24-hour 
ECG was performed, and therefore, it is not possible to 
evaluate cardiac repolarization both during a longer day-
time period and during sleep. The study was performed 
as a sub-analysis of a recently published RCT evaluating 
the effect of LVRS on endothelial function in severe 
COPD, and the power analysis was calculated to clarify 
this specific question  [18] . The negative findings of this 
study may therefore result from a lack of power. How-
ever, due to the observed CIs of the treatment effect, a 
reduction in QTc duration of >15.0 ms and in QT disper-
sion of >19.6 ms due to LVRS can be excluded. Thus, 
LVRS seems not to have a clinically significant effect on 
cardiac repolarization.
 Conclusion 
 This is the first RCT assessing the effect of LVRS on 
cardiac repolarization in COPD patients. The findings 
suggest that LVRS does not influence cardiac repolariza-
tion in patients with COPD and therefore, lung function 
impairment seems not to be a mechanism for altered car-
diac repolarization in COPD patients. However, it still 
remains unclear if hypoxia may is a mechanism leading 
to altered cardiac repolarization in patients with COPD.
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